| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Guanfacine hydrochloride |
| Brand | Intuniv® |
| Indication | For the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures. |
| Assessment Process | |
| Rapid review commissioned | 01/12/2015 |
| Rapid review completed | 18/12/2023 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended. |
